Challenges: The vast majority of individuals in the developed world have a family history of at least one type of cancer. Aside from major cancer syndromes where family histories point clearly towards a specific cancer site, family history information is not systematically used for the purpose of managing risk, of wisely using genetic testing, and of improving prevention practices. Strong evidence is emerging that syndromes once thought to be distinct, are overlapping in terms of the cancer site, and that several genetic factors increase the risk of multiple cancers. This opens important opportunities for screening and management of risk across clinical disciplines. A critical obstacle is the lack of software infrastructures and analytical approaches for capturing family history information across a large number of disease sites, for assessing whether the occurrence of multiple cancers in a family is likely to be random or hereditary;and for translating family history across multiple disease sites data into useful clinical decision tools.
Aims : Investigators in this proposal have developed the most detailed, accurate, and widely used tools for the breast-ovarian, colorectal, pancreatic, and skin cancer syndromes and the most widely used clinical tools to implement them, including CancerGene and HRA. All are freely available for research. The overall goal of this proposal is to lay the informatics and statistical foundations for both model implementation and clinical application of more comprehensive approaches. This cannot simply be addressed by juxtaposing software and algorithms that have been successful for single-syndrome models, but it requires novel strategies. Specifically, AIM 1 Is to develop software, including a) a general purpose open source risk calculator that can cover simultaneously an arbitrary number of cancer sites and, at the individual level, cancer-specific biomarkers, preventative interventions, and covariates;and b) tools for the implementation of the calculator in both primary and high risk clinical environments.
AIM 2 is to develop statistical methods to estimate the population parameters required by the general purpose calculator.
AIM 3 is to develop a proof-of-principle model covering about 10 disease sites, based on a comprehensive literature review of penetrance, interventions, and cancer markers. This will allow testing and troubleshooting of the clinical implementation and permit quantification of the benefits of clinical approaches using information across clinical disciplines. Impact: This research will have a direct impact by generating freely available computational and methodological resources for developing and implementing models that consider multiple syndromes. The hypothesis behind this proposal is that making these tools available can have a significant effect on: what data is collected;what use is made of this data across disease-specific programs;and whether individuals at increased risk receive appropriate attention in both early detection and treatment.

Public Health Relevance

The vast majority of individuals in the developed world have a family history of at least one type of cancer. Aside from major cancer syndromes where family histories point clearly towards a specific cancer site, family history information in largely untapped for the purpose of improving genetic testing and cancer prevention practices. A critical obstacle is the lack of software infrastructures and analytical approaches for capturing family history information across a large number of disease sites, for assessing whether the occurrence of cancers in the family is likely to be random or hereditary;and for translating data into useful clinical decision tools. This proposal is to develop the software and data analytic tools to deal with these issues.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA177233-01
Application #
8530798
Study Section
Special Emphasis Panel (ZRG1-HDM-Q (03))
Program Officer
Dunn, Michelle C
Project Start
2013-03-01
Project End
2015-02-28
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
1
Fiscal Year
2013
Total Cost
$225,021
Indirect Cost
$76,034
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Mazzola, Emanuele; Chipman, Jonathan; Cheng, Su-Chun et al. (2014) Recent BRCAPRO upgrades significantly improve calibration. Cancer Epidemiol Biomarkers Prev 23:1689-95